Guselkumab (Tremfya, Janssen-Cilag) is indicated for 'the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or biologic treatment'.
The dosage schedule is available in the summary of product characteristics for guselkumab.
The list price of guselkumab is (excluding VAT; company submission).
£4,500 for a 200 mg solution for infusion vial
£2,250 for a 200 mg pre-filled pen
£2,250 for a 100 mg pre-filled pen
The company has a commercial arrangement. This makes guselkumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, Janssen-Cilag did not disclose its Carbon Reduction Plan for UK carbon emissions.